Literature DB >> 31439217

Thromboembolic Risk After Atriopulmonary, Lateral Tunnel, and Extracardiac Conduit Fontan Surgery.

Catherine Deshaies1, Robert M Hamilton2, Azadeh Shohoudi3, Helen Trottier1, Nancy Poirier4, Jamil Aboulhosn5, Craig S Broberg6, Scott Cohen7, Stephen Cook8, Annie Dore9, Susan M Fernandes10, Anne Fournier1, Joseph Kay11, Blandine Mondésert9, François-Pierre Mongeon9, Alexander R Opotowsky12, Anna Proietti9, Jennifer Ting13, Ali Zaidi14, Paul Khairy15.   

Abstract

BACKGROUND: Thromboembolic events contribute greatly to morbidity and mortality following Fontan surgery for univentricular hearts.
OBJECTIVES: This study sought to evaluate the effect of type of Fontan surgery on thromboembolic risk.
METHODS: A North American multicenter retrospective cohort study enrolled 522 patients with Fontan palliation consisting of an atriopulmonary connection (APC) (21.4%), lateral tunnel (LT) (41.8%), or extracardiac conduit (EC) (36.8%). Thromboembolic complications and new-onset atrial arrhythmia were reviewed and classified by a blinded adjudicating committee. Thromboembolic risk across surgical techniques was assessed by multivariable competing-risk survival regression.
RESULTS: Over a median follow-up of 11.6 years, 10- and 20-year freedom from Fontan conversion, transplantation, or death was 94.7% and 78.9%, respectively. New-onset atrial arrhythmias occurred in 4.4, 1.2, and 1.0 cases per 100 person-years with APC, LT, and EC, respectively. APC was associated with a 2.82-fold higher risk of developing atrial arrhythmias (p < 0.001), with no difference between LT and EC (p = 0.95). A total of 71 thromboembolic events, 32 systemic and 39 venous, occurred in 12.8% of subjects, for an overall incidence of 1.1%/year. In multivariable analyses, EC was independently associated with a lower risk of systemic (hazard ratio [HR]: 0.20 vs. LT; 95% confidence interval [CI]: 0.04 to 0.97) and combined (HR: 0.34 vs. LT; 95% CI: 0.13 to 0.91) thromboembolic events. A lower incidence of combined thromboembolic events was also observed with antiplatelet agents (HR: 0.54; 95% CI: 0.32 to 0.92) but not anticoagulation (p = 0.53).
CONCLUSIONS: The EC Fontan was independently associated with a lower thromboembolic risk after controlling for time-varying effects of atrial arrhythmias and thromboprophylaxis.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fontan procedure; atrial arrhythmia; single ventricle; thromboembolism; thromboprophylaxis univentricular heart

Mesh:

Year:  2019        PMID: 31439217     DOI: 10.1016/j.jacc.2019.06.051

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

Review 1.  Evaluating the Longevity of the Fontan Pathway.

Authors:  John M Kelly; Gabriel J M Mirhaidari; Yu-Chun Chang; Toshiharu Shinoka; Christopher K Breuer; Andrew R Yates; Kan N Hor
Journal:  Pediatr Cardiol       Date:  2020-11-08       Impact factor: 1.655

2.  Recurrent sustained atrial arrhythmias and thromboembolism in Fontan patients with total cavopulmonary connection.

Authors:  Alexander C Egbe; William R Miranda; Janaki Devara; Likhita Shaik; Momina Iftikhar; Ahmed Goda Sakr; Anitha John; Ari Cedars; Fred Rodriguez; Jeremy P Moore; Matthew Russell; Jasmine Grewal; Salil Ginde; Adam M Lubert; Heidi M Connolly
Journal:  Int J Cardiol Heart Vasc       Date:  2021-03-15

3.  Increased Risk for Thromboembolism After Fontan Surgery: Considerations for Thromboprophylaxis.

Authors:  Suelyn Van Den Helm; Christopher Noel Sparks; Vera Ignjatovic; Paul Monagle; Chantal Attard
Journal:  Front Pediatr       Date:  2022-03-28       Impact factor: 3.418

4.  Hemodynamic performance of tissue-engineered vascular grafts in Fontan patients.

Authors:  Erica L Schwarz; John M Kelly; Kevin M Blum; Kan N Hor; Andrew R Yates; Jacob C Zbinden; Aekaansh Verma; Stephanie E Lindsey; Abhay B Ramachandra; Jason M Szafron; Jay D Humphrey; Toshiharu Shin'oka; Alison L Marsden; Christopher K Breuer
Journal:  NPJ Regen Med       Date:  2021-07-22

Review 5.  Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease.

Authors:  Eman Abdelghani; Clifford L Cua; Jean Giver; Vilmarie Rodriguez
Journal:  Cardiol Ther       Date:  2021-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.